Trial Profile
Prospective study of prevention of recurrence of prostate cancer with bone metastasis and prevention of bone mineral density decrease by combination therapy with hormonal therapy and zoledronic acid
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2014
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 05 Nov 2014 New trial record